Track topics on Twitter Track topics that are important to you
MISSISSAUGA, ON--(Marketwired - October 19, 2016) - Rob von der Porten, President and CEO of MedX Health Corp. ("MedX") (TSX VENTURE: MDX), a medical device company, today announced that Ms. Deborah Thompson, a veteran media and investor relations professional from Bay Street, has been retained to provide media relations and strategic communications advice to MedX.
MedX is a medical device company focused on skin cancer. It develops, manufactures and markets skin scanning devices based on its SIAscopy™ technology which lends itself to telemedicine applications so that dermatologists can evaluate moles and lesions remotely. MedX markets its SIAscopy products throughout Canada, the US, Europe and Asia.
Ms. Thompson has advised companies and senior management across many sectors, including: bio-med, technology, financial services, regulatory, legal, and environment, in North America and internationally.
"MedX is at an important inflection point in our growth trajectory, and we are very pleased to have Deborah assisting us with our communications and outreach to our many stakeholders, which include medical professionals, clients, governments, regulators, investors and the public," Mr. von der Porten said. "We are poised to significantly grow our business around the world," he added.
"I am thrilled to be working with MedX and believe that their devices are game-changers for the way in which skin cancers, globally, are detected. MedX offers cost-effective, fast and accurate methods to help identify and combat what can be devastating health outcomes if not caught early," Ms. Thompson said.
Prior to her communications practice, Ms. Thompson was the Editor in RBC Dominion Securities' Research Department, and was Vice President, Institutional and International Marketing, at Royal Bank Investment Management. In addition, she was Chief Canadian Correspondent at Knight Ridder Financial News (Dow Jones). Ms. Thompson has completed the Strategic Management of Investor Relations program, Ivey School of Business, and the Canadian Securities Course.
About MedX Health Corp.
MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIMSYS, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in pharmacies and remote clinics from where the images are sent to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia, the European Union and Turkey. SIAMETRICS™ is a unique product used in a specialized market for research into the clinical effectiveness of medical treatments of certain skin conditions. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
The role of medical devices in healthcare is essential. The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare. Covering a wide range of products, from simple bandages to the...
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...